Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice

Despite the elimination of smallpox, orthopoxviruses continue to be a source of biological danger for humans, as cowpox and monkey pox viruses circulate in nature and the last virus can cause both sporadic cases of human diseases and outbreaks of smallpox-like infection. In addition, periodic vaccin...

Full description

Saved in:
Bibliographic Details
Main Authors: Ya. A. Khlusevich, A. L. Matveev, E. P. Goncharova, I. K. Baykov, N. V. Tikunova
Format: Article
Language:English
Published: Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders 2019-07-01
Series:Вавиловский журнал генетики и селекции
Subjects:
Online Access:https://vavilov.elpub.ru/jour/article/view/2130
Tags: Add Tag
No Tags, Be the first to tag this record!
_version_ 1832575197319790592
author Ya. A. Khlusevich
A. L. Matveev
E. P. Goncharova
I. K. Baykov
N. V. Tikunova
author_facet Ya. A. Khlusevich
A. L. Matveev
E. P. Goncharova
I. K. Baykov
N. V. Tikunova
author_sort Ya. A. Khlusevich
collection DOAJ
description Despite the elimination of smallpox, orthopoxviruses continue to be a source of biological danger for humans, as cowpox and monkey pox viruses circulate in nature and the last virus can cause both sporadic cases of human diseases and outbreaks of smallpox-like infection. In addition, periodic vaccination is necessary for representatives of some professions (scientists studying pathogenic orthopoxviruses, medical personnel, etc.). Vaccination against smallpox virus with live vaccinia virus, which was widely used during the elimination of smallpox, induces the formation of long-term immunity in vaccinated people. However, providing a high level of protection, the vaccination is often accompanied by serious post-vaccination complications, the probability of which is particularly great for individuals with compromised immunity. In this regard, the development of preparations for the prevention and treatment of infections caused by orthopoxviruses remains important today. The aim of this study was to assess the immunogenicity in the mouse model of recombinant protein р35Δ12, designed previously on the base of the cowpox virus protein p35. It was previously shown that the protein р35Δ12 was recognized by fully human neutralizing anti-orthopoxviral antibody with high affinity. In this work, recombinant protein р35Δ12 produced in E. coli cells XL1-blue and purified by chromatography was used for two-time immunization of mice. Two weeks after the second immunization, blood samples were taken from mice and serum antibodies were analyzed. It was shown by ELISA and Western-blot analysis that immunized mice sera contained IgG antibodies specific to recombinant protein р35Δ12. Confocal microscopy showed that antibodies induced by the р35Δ12 protein were able to recognize Vero E6 cells infected with the LIVP-GFP vaccinia virus. In addition, the antibodies in the serum of immunized mice were able to neutralize the infectivity of the vaccinia virus LIVP-GFP in the plaque reduction neutralization test in vitro. These experiments have demonstrated promising properties of the р35Δ12 protein if it were used as a component of vaccine for prophylaxis of orthopoxvirus infections.
format Article
id doaj-art-f17a711de43b44899231d30fe97fa33f
institution Kabale University
issn 2500-3259
language English
publishDate 2019-07-01
publisher Siberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and Breeders
record_format Article
series Вавиловский журнал генетики и селекции
spelling doaj-art-f17a711de43b44899231d30fe97fa33f2025-02-01T09:58:07ZengSiberian Branch of the Russian Academy of Sciences, Federal Research Center Institute of Cytology and Genetics, The Vavilov Society of Geneticists and BreedersВавиловский журнал генетики и селекции2500-32592019-07-0123439840410.18699/VJ19.508920Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in miceYa. A. Khlusevich0A. L. Matveev1E. P. Goncharova2I. K. Baykov3N. V. Tikunova4Institute of Сhemical Biology аnd Fundamental Medicine, SB RASInstitute of Сhemical Biology аnd Fundamental Medicine, SB RAS; Novosibirsk State UniversityInstitute of Сhemical Biology аnd Fundamental Medicine, SB RASInstitute of Сhemical Biology аnd Fundamental Medicine, SB RASInstitute of Сhemical Biology аnd Fundamental Medicine, SB RAS; Novosibirsk State UniversityDespite the elimination of smallpox, orthopoxviruses continue to be a source of biological danger for humans, as cowpox and monkey pox viruses circulate in nature and the last virus can cause both sporadic cases of human diseases and outbreaks of smallpox-like infection. In addition, periodic vaccination is necessary for representatives of some professions (scientists studying pathogenic orthopoxviruses, medical personnel, etc.). Vaccination against smallpox virus with live vaccinia virus, which was widely used during the elimination of smallpox, induces the formation of long-term immunity in vaccinated people. However, providing a high level of protection, the vaccination is often accompanied by serious post-vaccination complications, the probability of which is particularly great for individuals with compromised immunity. In this regard, the development of preparations for the prevention and treatment of infections caused by orthopoxviruses remains important today. The aim of this study was to assess the immunogenicity in the mouse model of recombinant protein р35Δ12, designed previously on the base of the cowpox virus protein p35. It was previously shown that the protein р35Δ12 was recognized by fully human neutralizing anti-orthopoxviral antibody with high affinity. In this work, recombinant protein р35Δ12 produced in E. coli cells XL1-blue and purified by chromatography was used for two-time immunization of mice. Two weeks after the second immunization, blood samples were taken from mice and serum antibodies were analyzed. It was shown by ELISA and Western-blot analysis that immunized mice sera contained IgG antibodies specific to recombinant protein р35Δ12. Confocal microscopy showed that antibodies induced by the р35Δ12 protein were able to recognize Vero E6 cells infected with the LIVP-GFP vaccinia virus. In addition, the antibodies in the serum of immunized mice were able to neutralize the infectivity of the vaccinia virus LIVP-GFP in the plaque reduction neutralization test in vitro. These experiments have demonstrated promising properties of the р35Δ12 protein if it were used as a component of vaccine for prophylaxis of orthopoxvirus infections.https://vavilov.elpub.ru/jour/article/view/2130p35 orthopoxvirus proteincowpox virusrecombinant proteinimmunizationconfocal microscopy
spellingShingle Ya. A. Khlusevich
A. L. Matveev
E. P. Goncharova
I. K. Baykov
N. V. Tikunova
Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
Вавиловский журнал генетики и селекции
p35 orthopoxvirus protein
cowpox virus
recombinant protein
immunization
confocal microscopy
title Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
title_full Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
title_fullStr Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
title_full_unstemmed Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
title_short Immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
title_sort immunogenicity of recombinant fragment of orthopoxvirus p35 protein in mice
topic p35 orthopoxvirus protein
cowpox virus
recombinant protein
immunization
confocal microscopy
url https://vavilov.elpub.ru/jour/article/view/2130
work_keys_str_mv AT yaakhlusevich immunogenicityofrecombinantfragmentoforthopoxvirusp35proteininmice
AT almatveev immunogenicityofrecombinantfragmentoforthopoxvirusp35proteininmice
AT epgoncharova immunogenicityofrecombinantfragmentoforthopoxvirusp35proteininmice
AT ikbaykov immunogenicityofrecombinantfragmentoforthopoxvirusp35proteininmice
AT nvtikunova immunogenicityofrecombinantfragmentoforthopoxvirusp35proteininmice